ECOFECT


Rencontre et conférence de la société Antabio sur l'antibio-résistance ANNULEE

Colloque / Séminaire

Share |

le 8 avril 2015 /

ANNULATION DE LA CONFERENCE CE 8 AVRIL 2015

La société Antabio (http://www.antabio.com/), spécialisée dans la découverte et le développement de molécules contre les bactéries multi-résistantes aux traitements, souhaite établir des partenariats avec des équipes de recherche publique à Lyon.

Dans cet objectif, Marc Lemonnier, son PDG, donnera une conférence le 8 avril de 11h à 12h30 sur « Antibacterial drug discovery in the era of pan-antibiotic resistance ».

Des rencontres en tête-à-tête seront organisées l’après-midi avec les chercheurs désirant le rencontrer.

Date et lieu : 8 avril 2015 à l’IBCP

Résumé de la conférence : “Antibacterial drug discovery in the era of pan-antibiotic resistance”
Antibiotic resistance is a growing global health problem recognized as n°1 priority by the WHO. 5-10% of hospital patients in US and Europe develop a hospital-acquired (nosocomial) infection with annual  > 25,000 deaths and > €30 billion additional costs to public health due to drug-resistant bacterial infections. The urgent need for innovative antibacterial discovery due to the emergence of drug resistance and pharma’s focus on late stage drug development represents an opportunity for small drug discovery firms. Antabio SAS is a young private biopharmaceutical company with presence in France and the UK, dedicated to the discovery of game-changing treatments of life-threatening and drug-resistant bacterial infections. Ongoing discovery programs at the company focus on the development of new combination and/or adjunctive antibiotic therapies, whereby small molecule compounds targeting key bacterial resistance and pathogenicity mechanisms are coadministered with antibiotics to enhance their effectiveness. These programs address areas of highest unmet need such as infections caused by multi-drug resistant Gram-negative pathogens for which there are no available treatments, e.g. metallo ß-lactamase (MBL) producer superbugs currently spreading worldwide.

Contacts : laurence.naiglin@univ-lyon1.fr (ECOFECT), erwan.gueguen@univ-lyon1.fr (MAP), suzana.salcedo@ibcp.fr (IBCP)